# INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer

> **NCT04781725** · PHASE2 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** INT230-6
- **OTHER:** Saline injection

## Key facts

- **NCT ID:** NCT04781725
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-25
- **Primary completion:** 2022-03-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04781725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04781725, "INVINCIBLE TRIAL: Intratumoral INT230-6 in Breast Cancer". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT04781725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*